Skip to main content
Top
Published in: Endocrine Pathology 2/2013

01-06-2013

BRAF and RAS Mutations in Follicular Variants of Papillary Thyroid Carcinoma

Authors: Ji Young Park, Wook Youn Kim, Tae Sook Hwang, Sang Sook Lee, Hyunkyung Kim, Hye Seung Han, So Dug Lim, Wan Seop Kim, Young Bum Yoo, Kyoung Sik Park

Published in: Endocrine Pathology | Issue 2/2013

Login to get access

Abstract

Follicular variants of papillary thyroid carcinoma (FVPTC), particularly the encapsulated subtype, often cause a diagnostic dilemma. Therefore, many FVPTCs are interpreted as “indeterminate” in preoperative fine-needle aspiration (FNA). The aim of this study was to analyze the genotypic changes in BRAF codons 600 and 601, as well as the N, H, and KRAS codons 12, 13, and 61 in FVPTCs and investigate the usefulness of preoperative BRAF and RAS mutation analysis as an adjunct diagnostic tool along with routine FNA. Surgically resected thyroid nodules were reviewed to establish the histological diagnosis of FVPTC. All preoperative FNA diagnoses were categorized according to the Bethesda Reporting System. Mutations in BRAF codons 600 and 601, and N, H, KRAS codons 12, 13, and 61 were analyzed by pyrosequencing. Of 132 cases, 81 (61.4 %) had a point mutation in one of the BRAF V600E, BRAF K601E, or RAS oncogenes; BRAF V600E in 43(32.6 %), BRAF K601E in three (2.3 %), and RAS in 35 (26.5 %) cases. All mutations were mutually exclusive. Of 78 cases with an FNA indeterminate category diagnosis, 51 (65.4 %) were positive for mutations: 24 for BRAF V600E, 3 for BRAF K601E, and 24 for the RAS gene. The KRAS mutation was more frequently found than the HRAS mutation, comprising 22.9 % of the RAS mutations, and all KRAS mutations were located at codon 61. This study demonstrated that either BRAF or RAS mutations were present in two thirds of FVPTCs and these mutations were mutually exclusive.
Literature
1.
3.
go back to reference Ezzat S, Sarti DA, Cain DR, Braunstein GD Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154: 1838–1840, 1994.PubMedCrossRef Ezzat S, Sarti DA, Cain DR, Braunstein GD Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154: 1838–1840, 1994.PubMedCrossRef
4.
go back to reference Kang HW, No JH, Chung JH, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14: 29–33, 2004.PubMedCrossRef Kang HW, No JH, Chung JH, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14: 29–33, 2004.PubMedCrossRef
5.
go back to reference Meier CA Thyroid nodules: pathogenesis, diagnosis and treatment. Baillieres Best Pract Res Clin Endocrinol Metab 14: 559–575, 2000.PubMedCrossRef Meier CA Thyroid nodules: pathogenesis, diagnosis and treatment. Baillieres Best Pract Res Clin Endocrinol Metab 14: 559–575, 2000.PubMedCrossRef
6.
go back to reference Lee HK, Hur MH, Ahn SM Diagnosis of occult thyroid carcinoma by ultrasonography. Yonsei Med J 44: 1040–1044, 2003.PubMed Lee HK, Hur MH, Ahn SM Diagnosis of occult thyroid carcinoma by ultrasonography. Yonsei Med J 44: 1040–1044, 2003.PubMed
7.
go back to reference Baloch ZW, Shafique K, Flannagan M, Livolsi VA Encapsulated classic and follicular variants of papillary thyroid carcinoma: comparative clinicopathologic study. Endocr Pract 16: 952–959, 2010.PubMedCrossRef Baloch ZW, Shafique K, Flannagan M, Livolsi VA Encapsulated classic and follicular variants of papillary thyroid carcinoma: comparative clinicopathologic study. Endocr Pract 16: 952–959, 2010.PubMedCrossRef
8.
go back to reference Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55: 805–828, 1985.PubMedCrossRef Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55: 805–828, 1985.PubMedCrossRef
9.
go back to reference Lam AK, Lo CY, Lam KS Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol 16: 323–330, 2005.PubMedCrossRef Lam AK, Lo CY, Lam KS Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol 16: 323–330, 2005.PubMedCrossRef
10.
go back to reference Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116: 2974–2983, 2010.PubMedCrossRef Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116: 2974–2983, 2010.PubMedCrossRef
11.
go back to reference Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318–2326, 2003.PubMedCrossRef Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318–2326, 2003.PubMedCrossRef
12.
go back to reference Castro P, Rebocho AP, Soares RJ et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220, 2006.PubMedCrossRef Castro P, Rebocho AP, Soares RJ et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220, 2006.PubMedCrossRef
13.
go back to reference Nikiforov YE, Biddinger PW, Thompson LDR Diagnostic pathology and molecular genetics of the thyroid. In: Nikiforov YE, Ohori NP (eds) Papillary carcinoma, 2nd ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 183-246, 2012. Nikiforov YE, Biddinger PW, Thompson LDR Diagnostic pathology and molecular genetics of the thyroid. In: Nikiforov YE, Ohori NP (eds) Papillary carcinoma, 2nd ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 183-246, 2012.
14.
go back to reference Faquin WC, Baloch ZW Fine-needle aspiration of follicular patterned lesions of the thyroid: Diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 38: 731–739, 2010.PubMed Faquin WC, Baloch ZW Fine-needle aspiration of follicular patterned lesions of the thyroid: Diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol 38: 731–739, 2010.PubMed
15.
go back to reference Ohori NP, Schoedel KE Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol 55: 492–498, 2011.PubMedCrossRef Ohori NP, Schoedel KE Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol 55: 492–498, 2011.PubMedCrossRef
16.
go back to reference Elsheikh TM, Asa SL, Chan JK et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 130: 736–744, 2008.PubMedCrossRef Elsheikh TM, Asa SL, Chan JK et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 130: 736–744, 2008.PubMedCrossRef
17.
go back to reference Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28: 1336–1340, 2004.PubMedCrossRef Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28: 1336–1340, 2004.PubMedCrossRef
18.
go back to reference Wu HH, Rose C, Elsheikh TM The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol 40: 399–403, 2012.PubMedCrossRef Wu HH, Rose C, Elsheikh TM The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol 40: 399–403, 2012.PubMedCrossRef
19.
go back to reference Nagarkatti SS, Faquin WC, Lubitz CC et al. Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 20: 60–65, 2013.PubMedCrossRef Nagarkatti SS, Faquin WC, Lubitz CC et al. Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 20: 60–65, 2013.PubMedCrossRef
20.
go back to reference Chung KW, Yang SK, Lee GK et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65: 660–666, 2006.CrossRef Chung KW, Yang SK, Lee GK et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65: 660–666, 2006.CrossRef
21.
go back to reference Kim SK, Kim DL, Han HS et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17: 118–125, 2008.PubMedCrossRef Kim SK, Kim DL, Han HS et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17: 118–125, 2008.PubMedCrossRef
22.
go back to reference Kim SK, Hwang TS, Yoo YB et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96: 658–664, 2011.PubMedCrossRef Kim SK, Hwang TS, Yoo YB et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 96: 658–664, 2011.PubMedCrossRef
23.
go back to reference Rivera M, Ricarte-Filho J, Knauf J et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191–1200, 2010.PubMedCrossRef Rivera M, Ricarte-Filho J, Knauf J et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23: 1191–1200, 2010.PubMedCrossRef
24.
go back to reference Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 42: 500–506, 2011.PubMedCrossRef Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 42: 500–506, 2011.PubMedCrossRef
25.
go back to reference Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202: 247–251, 2004.PubMedCrossRef Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202: 247–251, 2004.PubMedCrossRef
26.
go back to reference Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120: 71–77, 2003.PubMedCrossRef Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120: 71–77, 2003.PubMedCrossRef
27.
go back to reference Adeniran AJ, Zhu Z, Gandhi M et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216–222, 2006.PubMedCrossRef Adeniran AJ, Zhu Z, Gandhi M et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216–222, 2006.PubMedCrossRef
28.
go back to reference Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745–2752, 2003.PubMedCrossRef Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745–2752, 2003.PubMedCrossRef
29.
go back to reference Eszlinger M, Paschke R Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol 322: 29–37, 2010.PubMedCrossRef Eszlinger M, Paschke R Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol 322: 29–37, 2010.PubMedCrossRef
30.
go back to reference Di Cristofaro J, Marcy M, Vasko V et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 37: 824–830, 2006.PubMedCrossRef Di Cristofaro J, Marcy M, Vasko V et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 37: 824–830, 2006.PubMedCrossRef
31.
go back to reference Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94: 2092–2098, 2009.PubMedCrossRef Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94: 2092–2098, 2009.PubMedCrossRef
32.
go back to reference Lee EJ, Song KH, Kim DL, Jang YM, Hwang TS, Kim SK The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin Endocrinol (Oxf) 75: 844–850, 2011.CrossRef Lee EJ, Song KH, Kim DL, Jang YM, Hwang TS, Kim SK The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules. Clin Endocrinol (Oxf) 75: 844–850, 2011.CrossRef
33.
go back to reference Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16 Suppl 4: iv44–49, 2005.PubMedCrossRef Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 16 Suppl 4: iv44–49, 2005.PubMedCrossRef
34.
go back to reference Suda K, Tomizawa K, Mitsudomi T Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29: 49–60, 2010.PubMedCrossRef Suda K, Tomizawa K, Mitsudomi T Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29: 49–60, 2010.PubMedCrossRef
35.
go back to reference Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96: 3390–3397, 2011.PubMedCrossRef Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96: 3390–3397, 2011.PubMedCrossRef
36.
go back to reference Petersen GM, Boffetta P Carcinogenesis of pancreatic cancer: challenges, collaborations, progress. Mol Carcinog 51: 1–2, 2012.PubMedCrossRef Petersen GM, Boffetta P Carcinogenesis of pancreatic cancer: challenges, collaborations, progress. Mol Carcinog 51: 1–2, 2012.PubMedCrossRef
37.
go back to reference Goodrow T, Reynolds S, Maronpot R, Anderson M Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res 50: 4818–4823, 1990.PubMed Goodrow T, Reynolds S, Maronpot R, Anderson M Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res 50: 4818–4823, 1990.PubMed
38.
go back to reference Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer cytopathology 118: 17–23, 2010.PubMedCrossRef Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer cytopathology 118: 17–23, 2010.PubMedCrossRef
Metadata
Title
BRAF and RAS Mutations in Follicular Variants of Papillary Thyroid Carcinoma
Authors
Ji Young Park
Wook Youn Kim
Tae Sook Hwang
Sang Sook Lee
Hyunkyung Kim
Hye Seung Han
So Dug Lim
Wan Seop Kim
Young Bum Yoo
Kyoung Sik Park
Publication date
01-06-2013
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2013
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-013-9244-0

Other articles of this Issue 2/2013

Endocrine Pathology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.